29,048 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the third quarter, Holdings Channel reports. The firm bought 29,048 shares of the company’s stock, valued at approximately $284,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Persistent Asset Partners Ltd boosted its holdings in Olema Pharmaceuticals by 153.8% during the second quarter. Persistent Asset Partners Ltd now owns 58,333 shares of the company’s stock valued at $248,000 after acquiring an additional 35,345 shares during the period. Titleist Asset Management LLC bought a new position in shares of Olema Pharmaceuticals in the second quarter worth about $64,000. Diadema Partners LP lifted its position in shares of Olema Pharmaceuticals by 153.7% during the 2nd quarter. Diadema Partners LP now owns 253,657 shares of the company’s stock worth $1,081,000 after purchasing an additional 153,657 shares during the last quarter. Birchview Capital LP acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth about $571,000. Finally, Farther Finance Advisors LLC boosted its stake in Olema Pharmaceuticals by 602.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after purchasing an additional 5,866 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Insiders Place Their Bets

In other news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the sale, the director owned 727,770 shares in the company, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David C. Myles sold 50,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $27.60, for a total value of $1,380,000.00. Following the completion of the sale, the insider owned 542,761 shares of the company’s stock, valued at approximately $14,980,203.60. This trade represents a 8.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 765,501 shares of company stock valued at $22,052,432. Company insiders own 16.36% of the company’s stock.

Olema Pharmaceuticals Trading Down 4.5%

Shares of OLMA stock opened at $25.23 on Friday. The company has a market capitalization of $1.73 billion, a P/E ratio of -13.49 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $26.89 and a 200 day moving average price of $14.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on OLMA shares. Guggenheim started coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright boosted their target price on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. The Goldman Sachs Group upped their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Oppenheimer increased their price target on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.